Literature DB >> 8166228

Vasoconstrictive peptides induce endothelin-1 and prostanoids in human cerebromicrovascular endothelium.

M Spatz1, D Stanimirovic, F Bacic, S Uematsu, R M McCarron.   

Abstract

Vasoconstrictive peptides and prostanoids have been implicated in the pathogenesis of hypertension and vasospasm. Recently, we have shown that human cerebromicrovascular endothelium [human brain endothelial cells (HBEC)] constitutively produces both endothelin-1 (ET-1) and prostanoids. The vasoactive peptides, arginine vasopressin (AVP) or angiotensin II (ANG II), stimulated secretion of both immunoreactive ET-1 and prostanoids from HBEC by a receptor-mediated induction of phospholipase C (PLC) and PLA2. The release of constitutive or AVP- or ANG II-induced ET-1 occurred at different rates during the 24-h incubation of HBEC in serum-free medium. The temporal profile of AVP-stimulated production of prostanoids differed from that of ANG II. AVP-induced release of prostaglandin D2 (PGD2) persisted for 24 h, whereas ANG II-stimulated PGD2 was only seen during the first 4 h of incubation. ANG II maximally stimulated PGI2 secretion during the 4- to 8-h interval, whereas AVP did not stimulate PGI2 secretion. Dexamethasone (Dxm), indomethacin (Indo), and nordihydroguaiaretic acid, the respective inhibitors of PLA2-cyclooxygenase II, cyclooxygenase, and lipoxygenase, increased both constitutive and AVP- or ANG II-stimulated secretion of ET-1. Dxm also decreased AVP- or ANG II-stimulated production of PGD2 and PGF2 alpha. These results indicate an interrelationship between HBEC production of ET-1 and prostanoids, which may play a role in regulating cerebral microcirculation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166228     DOI: 10.1152/ajpcell.1994.266.3.C654

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Mechanisms of AVP-induced glucagon release in clonal alpha-cells in-R1-G9: involvement of Ca(2+)-dependent and -independent pathways.

Authors:  S Yibchok-Anun; H Cheng; T H Chen; W H Hsu
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  L-type voltage-dependent Ca2+ channels in cerebral microvascular endothelial cells and ET-1 biosynthesis.

Authors:  Momoh A Yakubu; Charles W Leffler
Journal:  Am J Physiol Cell Physiol       Date:  2002-08-22       Impact factor: 4.249

3.  Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.

Authors:  Wiebke Fenske; Christoph Wanner; Bruno Allolio; Christiane Drechsler; Katja Blouin; Jürgen Lilienthal; Vera Krane
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

4.  Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors.

Authors:  Hiroshi Yamanari; Kazufumi Nakamura; Mikio Kakishita; Tohru Ohe
Journal:  Clin Cardiol       Date:  2004-09       Impact factor: 2.882

Review 5.  Pathophysiology of copeptin in kidney disease and hypertension.

Authors:  Baris Afsar
Journal:  Clin Hypertens       Date:  2017-06-13

6.  Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients.

Authors:  Maciej Fijałkowski; Krzysztof Safranow; Bengt Lindholm; Kazimierz Ciechanowski; Anna Maria Muraszko; Barbara Dołęgowska; Katarzyna Dołęgowska; Edyta Golembiewska
Journal:  Int Urol Nephrol       Date:  2019-06-11       Impact factor: 2.370

7.  Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5.

Authors:  Edyta Golembiewska; Abdul Rashid Qureshi; Lu Dai; Bengt Lindholm; Olof Heimbürger; Magnus Söderberg; Torkel B Brismar; Jonaz Ripsweden; Peter Barany; Richard J Johnson; Peter Stenvinkel
Journal:  BMC Nephrol       Date:  2020-02-07       Impact factor: 2.388

8.  Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells.

Authors:  J C Yu; J D Pickard; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.